Endocrinology: The next 60 years

Journal of Endocrinology

Volumn 190, Issue 1, 2006, Pages 3-6

  Ho, Ken K Y ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; HORMONE DERIVATIVE; HYDROCORTISONE;

AGING; CLINICAL CHEMISTRY; CLINICAL PRACTICE; COMBINATORIAL CHEMISTRY; CONSUMER; DRUG DELIVERY SYSTEM; DRUG RESEARCH; ENDOCRINE DISEASE; ENDOCRINOLOGY; EVIDENCE BASED MEDICINE; EXPECTATION; HORMONAL THERAPY; HUMAN; INFORMATION TECHNOLOGY; MEDICAL RESEARCH; MEDICAL SPECIALIST; MOLECULAR BIOLOGY; NOTE; OBESITY; PHARMACOGENOMICS; PRIORITY JOURNAL;

AGING; COSMETICS; ENDOCRINE SYSTEM DISEASES; ENDOCRINOLOGY; FORECASTING; HUMANS; INTERNET; PATIENT CARE;

EID: 33746745261     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06884     Document Type: Note

References (21)

1. Despres JP, Golay A & Sjostrom L 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 353 2121-2134.
2. Ellacott KL & Cone RD 2004 The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Progress in Hormone Research 59 395-408.
3. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK & He J 2005 Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365 1398-1405.
4. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ et al. 2003 Effects of estrogen plus progestin on health-related quality of life. New England Journal of Medicine 348 1839-1854.
5. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR & Flegal KM 2004 Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. Journal of the American Medical Association 291 2847-2850.
6. Lamberts SW, Romijn JA & Wiersinga WM 2003 The future endocrine patient. Reflections on the future of clinical endocrinology. European Journal of Endocrinology 149 169-175.
7. Lin S, Boey D & Herzog H 2004 NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 38 189-200.
8. McLellan F 2002 Obesity rising to alarming levels around the world. Lancet 359 1412.
9. National Center for Health Statistics 2005 Health, United States. Chartbook on Trends in the Health of Americans (accessed at http:// www.cdc.gov/nchs/hus.htm).
10. Powles J & Day N 2002 Interpreting the global burden of disease. Lancet 360 1342-1343.
11. Romijn JA, Smit JW & Lamberts SW 2003 Intrinsic imperfections of endocrine replacement therapy. European Journal of Endocrinology 149 91-97.
12. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD & Melmed S 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Journal of Clinical Investigation 100 2386-2392.
13. Smith R 2002 In search of 'non-disease'. British Medical Journal 324 883-885.
14. Strohman R 2002 Manoeuvring in the complex path from genotype to phenotype. Science 296 701-703.
15. Tattersall RL 2002 The expert patient: a new approach to chronic disease management for the twenty-first century. Clinical Medicine 2 227-229.
16. WHO 2006 Ageing and Life Course (accessed at www.who.int/ageing/en).
17. Wilke RA, Reif DM & Moore JH 2005 Combinatorial pharmacogenetics. Nature Reviews. Drug Discovery 4 911-918.
18. Wilson JD 2005 The evolution of endocrinology. Clinical Endocrinology (Oxford) 62 389-396.
19. Wyatt JC & Sullivan F 2005 eHealth and the future: promise or peril? British Medical Journal 331 1391-1393.
20. Yanovski SZ 2005 Pharmacotherapy for obesity-promise and uncertainty. New England Journal of Medicine 353 2187-2189.
21. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L et al. 2004 Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 89 5181-5188.